Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT
Published on: 19 November 2015
Skip to main content
Published on: 19 November 2015
Published on: 29 October 2015
Published on: 19 October 2015
Published on: 21 September 2015
Published on: 28 August 2015
Published on: 14 July 2015
Published on: 25 July 2011
Published on: 4 April 2013
Published on: 26 November 2013
Published on: 4 October 2012
Lars M Wagner, University of Kentucky, USA
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. In this review, Dr Lars Wagner summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. He also discusses new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.
Dr Paolo G Casali is head of the Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. He serves as Secretary of the Ethics Committee of his institution. His research focuses on rare tumors, especially adult sarcomas, including gastrointestinal stromal tumors (GIST), and uncommon histological types. He is the Secretary of the Italian Sarcoma Group, and is a member of the EORTC Soft Tissue & Bone Sarcoma Group. He chairs the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which endeavours to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers. He acts as an Editor of START, an Italian-based, European state-of-the-art instrument on cancer treatment. He is a member of the Executive Board of ESMO as chair of the Public Policy/European Affairs Committee, and is Faculty Coordinator for Sarcoma. He is a member of the Policy Committee of ECCO. He teaches Medical Therapy of Rare Cancers at the Milan University postgraduate school in Oncology.
Dr. Angelo Paolo Dei Tos is the Director of the Department of Oncology and Director of Anatomic Pathology at the General Hospital in Treviso, Italy, and Contract Professor of Pathology at the University of Padua School of Medicine. He is the Chairman of the Pathology Subcommittee of the Soft Tissue and Bone Group of EORTC, Founder and Past Chairman of the Working Group on Soft Tissue Tumor Pathology of the European Society of Pathology, Past President of the International Society of Bone and Soft Tissue Pathology, panel member for the WHO classification of Bone and Soft Tissue Sarcomas, member of the Board of Directors of the Connective Tissue Oncologic Society, and a faculty member of ESMO. He has authored or co-authored more than 140 peer reviewed scientific papers.
The journal is an integral part of the euroSARC project funded by the European Commission through the 7th Framework Programme under Grant Agreement no. 278742.